| Identification | Back Directory | [Name]
Pexiganan | [CAS]
147664-63-9 | [Synonyms]
Pexiganan Acetate
Pexiganan USP/EP/BP
L-Lysinamide, glycyl-L-isoleucylglycyl-L-lysyl-L-phenylalanyl-L-leucyl-L-lysyl-L-lysyl-L-alanyl-L-lysyl-L-lysyl-L-phenylalanylglycyl-L-lysyl-L-alanyl-L-phenylalanyl-L-valyl-L-lysyl-L-isoleucyl-L-leucyl-L-lysyl- | [Molecular Formula]
C122H210N32O22 | [MDL Number]
MFCD07772290 | [MOL File]
147664-63-9.mol | [Molecular Weight]
2477.17 |
| Hazard Information | Back Directory | [Uses]
Pexiganan (MSI 78 free base) is a synthetic analog of magainin 2. Pexiganan is a potent and orally active broad-spectrum antimicrobial peptide. Pexiganan can be used in the research of infections, such as diabetic foot ulcer infections[1]. | [in vivo]
Pexiganan (1, 3, 10 or 30 mg/kg, p.o., daily for three consecutive days) shows H. pylori clearance efficiency in H. pylori-infected mouse[3].
Pexiganan (1 mg/kg, i.p.) shows antimicrobial activity in rat models of Gram-negative septic shock[4].
| Animal Model: | H. pylori-infected mouse[3]. | | Dosage: | 1, 3, 10 or 30 mg/kg | | Administration: | Oral administration, daily for three consecutive days. | | Result: | Lowered H. pylori urease activities in mouse stomachs. |
| Animal Model: | Rat models of Gram-negative septic shock (induced by E.coli ATCC 25922)[4]. | | Dosage: | 1 mg/kg | | Administration: | Intraperitoneal injection (i.p.) | | Result: | Displayed antimicrobial activities and survival rates of 67.7%. |
| [References]
[1] Lamb HM, et al. Pexiganan acetate. Drugs. 1998 Dec;56(6):1047-52; discussion 1053-4. DOI:10.2165/00003495-199856060-00011
[2] Ge Y, et al. In vitro antibacterial properties of pexiganan, an analog of magainin. Antimicrob Agents Chemother. 1999 Apr;43(4):782-8. DOI:10.1128/AAC.43.4.782
[3] Zhang XL, et al. The synthetic antimicrobial peptide pexiganan and its nanoparticles (PNPs) exhibit the anti-helicobacter pylori activity in vitro and in vivo. Molecules. 2015 Mar 2;20(3):3972-85. DOI:10.3390/molecules20033972
[4] Giacometti A, et al. Effects of pexiganan alone and combined with betalactams in experimental endotoxic shock. Peptides. 2005 Feb;26(2):207-16. DOI:10.1016/j.peptides.2004.09.012 |
|
|